Seeking Alpha
 

Roche Holding Ltd ADR (RHHBY)

- OTCQX
  • Wed, Feb. 18, 5:41 PM
    • In an NIH-sponsored Diabetic Retinopathy Clinical Research Network comparative effectiveness study published in the New England Journal of Medicine, Regeneron Pharmaceuticals' (NASDAQ:REGN) Eylea (aflibercept) was more effective than Genentech's (OTCQX:RHHBY) Avastin (bevacizumab) and Lucentis (ranibizumab). The 660-patient study was designed to compare three anti-VEGF therapies for the treatment of diabetic macular edema.
    • Eylea demonstrated significantly greater improvement in mean visual acuity letter score at one year, the primary efficacy endpoint, than the comparators. Eylea's score was +13 letters from baseline versus +11 for Lucentis and +10 for Avastin.
    • In patients with moderate or worse vision loss at the start of the trial, Eylea showed a statistically significant seven-letter (~1.5 lines on an eye chart) improvement over Avastin and a five-letter improvement over Lucentis (Eylea: +19 letters from baseline; Lucentis: +14; Avastin: +12).
    • 42% of patients receiving Eylea gained at least 15 letters in best corrected visual acuity (BCVA) from baseline compared to 32% for Lucentis and 29% for Avastin.
    • Eylea accounts for almost all of Regeneron's product revenue, posting $1.7B in sales last year.
    • Investigators intend to present the results at next week's Annual Macula Society Meeting in Scottsdale, AZ.
    | 8 Comments
  • Tue, Feb. 10, 10:05 AM
    • Pfenex (PFNX +25.9%) and Hospira (HSP +0.1%) team up to develop and commercialize PF582, Pfenex's lead biosimilar candidate to Genentech's (OTCQX:RHHBY +0.8%) Lucentis (ranibizumab), which logged ~$4B in sales last year.
    • Under the terms of the collaboration, Pfenex will receive an upfront payment of $51M, once the agreement clears antitrust review, and up to $291M in development and sales milestones plus tiered double-digit royalties on commercial sales.
    • The companies will share the Phase 3 equivalence clinical trial costs. Hospira will be responsible for manufacturing and commercializing PF582 worldwide.
    | Comment!
  • Mon, Feb. 9, 4:01 PM
    • Roche (OTCQX:RHHBY -2.5%) acquires Potsdam, Germany-based Signature Diagnostics AG, a translational oncology and genomics company that develops large blood plasma and tissue biobanks in multiple cancers that are constructed from multicenter prospective clinical studies. Signature uses its biobank samples with clinical progression and genetic data to develop and validate circulating cell-free DNA (cfDNA) tests, which show promise in non-invasive treatment response monitoring.
    • Roche intends to leverage Signature's expertise in cancer biobanks and next generation sequencing (NGS) assay development to accelerate the development of targeted NGS-based diagnostics.
    • Specific terms of the deal are undisclosed.
    | Comment!
  • Sat, Feb. 7, 11:53 AM
    | Comment!
  • Fri, Feb. 6, 10:30 AM
    • Today is the PDUFA date for the FDA's review of Genentech's (OTCQX:RHHBY) supplemental Biologics License Application (sBLA) submitted on August 7 for the use of Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy, an eye disease affecting nearly 8M Americans.
    • Lucentis is currently cleared for the treatment of wet age-related macular degeneration, macular edema following retinal vein occlusion and diabetic macular edema.
    • Previously: FDA accepts sBLA for Lucentis label expansion (Oct. 8, 2014)
    | Comment!
  • Wed, Feb. 4, 7:23 AM
    • On the basis of an pre-planned interim analysis by an independent data monitoring committee, a Phase 3 clinical trial assessing Roche's (OTCQX:RHHBY) Gazyva (obinutuzumab) in patients with refractory indolent non-Hodgkin's lymphoma was ended early after it was determined that it met its primary endpoint. The results showed that patients treated with Gazyva plus bendamustine followed by Gazyva alone lived significantly longer without disease worsening or death (progression-free survival or PFS) that those treated with bendamustine alone. The study was stopped because the benefit was profound with no unexpected adverse events.
    • The data will be presented at a future medical conference and will be used in regulatory applications in the U.S. and E.U.
    • Gazyva/Gazyvaro is a monoclonal antibody designed to attach to a B-cell surface protein called CD20. Along with the body's immune system, it attacks and kills targeted cells. It is approved in more than 40 countries, in combination with chlorambucil, for the treatment of treatment-naive chronic lymphocytic leukemia.
    | Comment!
  • Mon, Feb. 2, 7:05 AM
    • The FDA designates Roche's (OTCQX:RHHBY) investigational cancer immunotherapy, MPDL3280A, a Breakthrough Therapy for the treatment of patients with PD-L1-positive non-small cell lung cancer (NSCLC) whose disease has progressed or after platinum-based chemotherapy (and appropriate targeted therapy for those with an EGFR mutation-positive or ALK-positive tumor).
    • This is the second BTD tag for the product candidate. The first, for metastatic bladder cancer, was granted in 2014.
    • Breakthrough Therapy status allows a more rapid review of the New Drug Application (NDA) or Biologics License Application (BLA), including allowing the submission after a Phase 2 trial, in certain cases.
    • Roche intends to initiate new Phase 3 studies this year evaluating MPDL3280A in additional tumor types.
    | Comment!
  • Thu, Jan. 29, 9:12 AM
    • Roche (OTCQX:RHHBY) and Qualcomm subsidiary Qualcomm Life enter into a strategic collaboration to improve remote monitoring and management of chronic disease patients. Roche will use Qualcomm Life's wireless 2net platform to seamlessly and securely capture data from a patient's medical devices and transmit it to Roche's cloud-based back-end services. The initiative will start with anticoagulation meters.
    • Roche Point of Care SVP Jeremy Moss says, "This collaboration marks a significant milestone for Roche as we launch a new generation of point-of-care solutions that enable healthcare professionals to better keep in touch remotely with patients, whenever and wherever they are. By combining Qualcomm Life's leadership in powering connected health solutions with our point-of-care expertise, we are taking an important step forward to realize our connected care strategy, ultimately enabling physicians to improve the overall quality of life for patients."
    • Financial aspects of the partnership are undisclosed.
    | Comment!
  • Wed, Jan. 28, 7:31 AM
    • Roche (OTCQX:RHHBY) Q4 results (CHFm): Total Revenues: 12,705 (+6.6%); Pharmaceuticals: 9,731 (+6.8%), Diagnostics: 2,974 (+6.3%).
    • Pharmaceuticals: U.S.: 4,294 (+17.1%), Europe: 2,352 (+2.2%); Japan: 895 (-2.0%); International: 2,190 (-1.8%).
    • Sales By Product: MabThera/Rituxan: 1,776 (+1.8%), Avastin: 1,668 (+8.0%), Herceptin: 1,596 (+7.5%), Lucentis: 441 (+0.7%), Tarceva: 321 (0.0%), Actemra/RoActemra: 327 (+19.3%), Pegasys: 204 (-28.4%), Xolair: 507 (+153.5%), Perjeta: 285 (103.6%), Xeloda: 153 (-55.7%).
    | Comment!
  • Wed, Jan. 28, 3:23 AM
    • Missing analysts’ forecasts, Roche (OTCQX:RHHBY) said net income attributable to shareholders fell to 9.33B francs ($10.34B) from 11.16B francs a year earlier, despite rising sales of its cancer treatments.
    • The company said it was hit by impairments, restructuring costs and debt restructuring.
    • Roche expects sales this year to grow in low-to-mid single digits range, while core earnings per share should grow more than sales.
    • Roche shares are down 1.3% in Switzerland.
    | Comment!
  • Mon, Jan. 19, 5:26 PM
    | Comment!
  • Fri, Jan. 16, 6:14 AM
    • Looking to gain access to an experimental drug to treat spinal muscular atrophy, Roche (OTCQX:RHHBY) has agreed to buy privately-held Trophos.
    • The acquisition is the latest in a spate of deals by Roche, following its purchase of a $1B stake in Foundation Medicine and licensing agreement with Genome pioneer J. Craig Venter.
    • Under the terms of the agreement with Trophos, the French firm's shareholders will receive an upfront payment of €120M ($140M), plus further payments based on predetermined milestones worth up to €350M.
    • OTCQX:RHHBY -2.2% premarket
    | Comment!
  • Thu, Jan. 15, 8:40 AM
    • "Words fail me," says Swatch (OTCPK:SWGAY) CEO Nick Hayek. "Today's SNB action is a tsunami; for the export industry and for tourism, and finally for the entire country." Swatch is lower by 15.75% in European action.
    • Previously: Swiss shares crater after SNB abandons cap on euro (Jan. 15)
    • A sampling of others: Cement maker Holcim (OTCPK:HCMLY) is down 11.2%, Novartis (NYSE:NVS) is down 9%, Roche (OTCQX:RHHBY) is down 7.9%, Credit Suisse (NYSE:CS) is down 11.7%, and UBS (NYSE:OUBS) is down 10.8%.
    • The good news for ADR players is that's all action in Switzerland. Thanks to the franc's now 13.5% gain, the ADRs trading in the U.S. are likely all to be higher.
    | 12 Comments
  • Thu, Jan. 15, 7:50 AM
    • Roche's (OTCQX:RHHBY) Genentech unit signs a multi-year deal with genome pioneer J. Craig Venter's Human Longevity start-up to sequence and analyze tens of thousands of human genomes. The data will be used to identify new drug targets and biomarkers.
    • Human Longevity's goal is to sequence 1M genomes by 2020. The transaction will enable it to have access to both genomic and clinical information from patients enrolled in clinical trials. The DNA will be stripped of personal identifying details but will be linked to clinical information.
    • Financial terms are undisclosed.
    | Comment!
  • Wed, Jan. 14, 9:13 AM
    • Express Scripts' (NASDAQ:ESRX) success in containing the prices of new HCV therapies by pitting Gilead Sciences (NASDAQ:GILD) against AbbVie (NYSE:ABBV) is sending shock waves through the biotech/pharma industry. Most of the big players slumped yesterday as investors fear that ESRX's tactics will spread to other high cost areas like cancer and cholesterol.
    • At JPM15 yesterday, CEO George Paz said that the new cholesterol-lowering post-statin PCSK9 inhibitors will be the next big opportunity to pit drug firms against each other in order to drive costs down. FDA clearance of the first two therapies, one from Amgen (NASDAQ:AMGN) and the other from Regeneron Pharmaceuticals (NASDAQ:REGN) (NYSE:SNY), is expected to occur at about the same time.
    • The prices of emerging cancer therapies will also be in payers' crosshairs. Amgen's Blincyto, for example, costs $178,000 per standard course of treatment while Merck's (NYSE:MRK) Keytruda is close behind at $150,000.
    • Related tickers: (NYSE:AZN) (NYSE:GSK) (NYSE:LLY) (ABBV) (NYSE:PFE) (NASDAQ:BIIB) (NYSE:ABT) (NASDAQ:CELG) (NYSE:BMY) (OTCQX:RHHBY) (NYSE:JNJ) (NYSE:NVS) (OTCPK:BAYRY)
    | 56 Comments
  • Tue, Jan. 13, 7:06 AM
    • Roche (OTCQX:RHHBY) enters into a development and commercialization deal with Japan's Meiji Seika Pharma and Canada's Fedora for OP0595, a beta-lactamase inhibitor in Phase 1 development. Beta-lactamase inhibitors restore or potentiate the activity of beta-lactam antibiotics (e.g., penicillins, cephalosporins, monobactams) which is of keen interest from the medical community considering the ever-increasing threat of bacterial resistance.
    • Under the terms of the agreement, Roche obtains worldwide rights to OP0595 except Japan where Meiji retains rights. Meiji and Fedora will receive upfront payments and various milestones potentially up to $750M plus tiered royalties on commercial sales.
    | Comment!
Visit Seeking Alpha's
RHHBY vs. ETF Alternatives
Company Description
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and... More
Sector: Healthcare
Country: Switzerland